Global Blood Therapeutics Email Format

Pharmaceutical Manufacturing
10,001+ employees
New York, NY, USA

Global Blood Therapeutics is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for patients with sickle cell disease and other blood disorders.

Find contacts at Global Blood Therapeutics

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

firstinitiallast@gbt.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
2011
Headquarters
New York, NY, USA
Revenue
$50B-$100B
FUNDING Stage
Acquired
Key Executives
Albert Bourla (Chairman and Chief Executive Officer), Nazila Habibizad (Executive Vice President, Operations), Susan Rienow (Global Chief Marketing Officer)

Tech Stack

Salesforce

CRM

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Global Blood Therapeutics?

Global Blood Therapeutics uses the firstinitiallast format, so Jane Smith would be jsmith@gbt.com.

When was Global Blood Therapeutics founded, and what disease does it focus on?

Global Blood Therapeutics was founded in 2011 in South San Francisco and has focused exclusively on sickle cell disease since its inception, developing treatments aimed at addressing the root causes of this inherited blood disorder.

How does Global Blood Therapeutics fit into Pfizer's rare hematology portfolio?

Pfizer completed its acquisition of Global Blood Therapeutics in October 2022 for approximately 5.4 billion dollars, bringing GBT's sickle cell disease pipeline and expertise into Pfizer's rare hematology unit to strengthen its presence in that therapeutic area.

What is the current development status of osivelotor, the sickle cell drug originally developed by Global Blood Therapeutics?

Osivelotor, a next-generation hemoglobin S polymerization inhibitor originally developed by Global Blood Therapeutics, is in a Phase 2/3 clinical trial under Pfizer, though enrollment has been paused since late 2024 due to a partial FDA hold tied to safety concerns.

Can Clay help me find verified contact emails for Global Blood Therapeutics employees?

Yes, Clay can help you find and verify email addresses for Global Blood Therapeutics contacts using the firstinitiallast format at gbt.com, making it straightforward to build and enrich a targeted outreach list for the team.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles